ESCRS - PO218 - Patient-Reported Visual Function And Quality Of Life Outcomes With A Trifocal Iol – A Literature Review

Patient-Reported Visual Function And Quality Of Life Outcomes With A Trifocal Iol – A Literature Review

Published 2022 - 40th Congress of the ESCRS

Reference: PO218 | Type: Free paper | DOI: 10.82333/ae3j-xn28

Authors: Andrew Maxwell 1 , Margaret Ainslie-Garcia 2 , Mukesh Dhariwal 3 , Kayla Mills 3 , Derek O'Boyle* 4

1California Eye Institute,Fresno,United States, 2EVERSANA Life Science Services, LLC,Burlington,Canada, 3Global HEOR,Alcon Vision, LLC,Fort Worth,United States, 4Alcon,Dublin,Ireland

Purpose

AcrySof IQ PanOptix (TFNT00) is the first trifocal IOL launched in the USA in 2019. A literature review was conducted to identify recently published evidence of the patient reported outcomes (PRO) on improvement and/or satisfaction with visual function (VF) and quality of life (QoL) in TFNT00 recipients.

Setting

Global

Methods

MEDLINE and the Embase congress abstract database were searched from September-2019 to September-2021. Search terms included the technology name (TFNT00, PanOptix) and “quality of life” or “visual function”. Study design inclusion criteria included: randomized and observational clinical studies. Eight unique clinical studies (7 peer-reviewed publications and 1 congress abstract) reporting on the outcomes of interest were included in the review. PRO questionnaires used were the National Eye Institute refractive error (NEI-RE; N=1 study), the NEI-Visual Function (NEI-VF)-25 (N=2), the NEI-VF-14 (N=4), and the IOL Satisfaction questionnaire (IOLSAT; N=1).

Results

All studies using VF-14 reported mean scores of 94.9/100 or above in patients implanted with TFNT00 IOL. In studies reporting outcomes using VF-25 questionnaire, TFNT00 outperformed bilateral diffractive EDOF in one study (p<0.05; N=40 pts) and was comparable to mixed diffractive EDOF/bifocal in another (N=50 pts). In a prospective study, TFNT00 IOL demonstrated higher scores in 6/8 NEI-RE categories versus diffractive EDOF (p>0.05, N=50 pts). In an Investigational Device Exemption study, patients implanted with TFNT00 demonstrated very high satisfaction with TFNT00 (IOLSAT; N=129 pts), with >99% reporting they would implant TFNT00 again and >98% would recommend to friends or family.

Conclusions

This literature review demonstrates patients receiving TFNT00 IOL could achieve excellent visual function and vision-related quality of life outcomes. Statistical pooling of these data using meta-analytic techniques could further help to improve confidence in conclusions.